Literature DB >> 1742854

Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer.

H Wilke1, P Preusser, M Stahl, A Harstrick, H J Meyer, W Achterrath, H J Schmoll, S Seeber.   

Abstract

A group of 20 patients with gastric cancer, refractory to or with no change after two or three cycles of carboplatin were treated with etoposide/folinic acid/5-fluorouracil (ELF). An objective remission rate of 45% (9/20), a median remission duration of 8 months and a median survival time of 11 months were achieved. Toxicities were mild to moderate only. These results are comparable to those being achieved with ELF in previously untreated gastric cancer patients and confirm its efficacy and good tolerability.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1742854     DOI： 10.1007/bf00686342

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

1.  High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.

Authors:  H Wilke; P Preusser; U Fink; W Achterrath; L Lenaz; M Stahl; C Schober; H Link; H J Meyer; B Lucke
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Phase II study of carboplatin in untreated inoperable advanced stomach cancer.

Authors:  P Preusser; H Wilke; W Achterrath; L Lenaz; M Stahl; J Casper; H J Meyer; J Meyer; M Blum; H J Schmoll
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

3.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.

Authors:  P Preusser; H Wilke; W Achterrath; U Fink; L Lenaz; A Heinicke; J Meyer; H J Meyer; H Buente
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

4.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

5.  New developments in the treatment of gastric carcinoma.

Authors:  H Wilke; P Preusser; U Fink; W Achterrath; H J Meyer; M Stahl; L Lenaz; J Meyer; J R Siewert; H Geerlings
Journal:  Semin Oncol       Date:  1990-02       Impact factor: 4.929
  5 in total
  4 in total

1.  Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers.

Authors:  Henning Schulze-Bergkamen; Ivan Zuna; Andreas Teufel; Wolfgang Stremmel; Jochen Rudi
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Perspectives of surgery and multimodality treatment in gastric carcinoma.

Authors:  H J Meyer; J Jähne; H Wilke
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.

Authors:  S Cascinu; A Fedeli; G Catalano
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients.

Authors:  K Nordin; J Steel; K Hoffman; B Glimelius
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.